Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.

Gregory J Dore | Jordan J Feld | Alex Thompson | Marianne Martinello | Andrew J Muir | Kosh Agarwal | Beat Müllhaupt | Heiner Wedemeyer | Karine Lacombe | Gail V Matthews | Michael Schultz | Marina Klein | Christophe Hezode | Gerard Estivill Mercade | Danny Kho | Kathy Petoumenos | Philippa Marks | Fernando Tatsch | Ana Gabriela Pires Dos Santos | Ed Gane | SMART-C Study Group
Journal of hepatology | 2020

Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule.

Pubmed ID: 31655134

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


AbbVie (tool)

RRID:SCR_010484

A research-based biopharmaceutical company that develops advanced therapies to address global health problems.

View all literature mentions